Biocon Biologics' antibody drug unit in Bengaluru gets EU GMP certificate

Approval comes from Irish health regulator, which had flagged some deficiencies in the manufacturing process iin May

Biocon Biologics
Sohini Das Mumbai
2 min read Last Updated : Jul 06 2022 | 11:56 PM IST
Biocon Biologics Ltd., a subsidiary of Biocon, has received a EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022, the company said.

The facility, spread across 340,000-square feet, will enhance Biocon Biologics' capabilities manifold to manufacture drug substances in its mAbs portfolio.

"This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing. Upon successful completion and qualification in 2021, it was awarded the Facility of the Year Award with an Honorable Mention by the International Society for Pharmaceutical Engineering,” said a company spokesperson.

In May the company had said that Ireland's health regulator has reported some deficiencies in the manufacturing process at the company's plant.

"The inspection report contains no 'critical' observations and only one of the deficiencies is categorised as 'major' which is being addressed expeditiously in consultation with the regulatory agency," the spokesperson had said.

The facility will help the company address the additional requirements of products in the European Union market, the company had said.

Biocon Biologics has recently acquired Viatris’ biosimilars business in a $3.3 billion cash and stock deal. The transaction is expected to close in the second half of 2022, subject to satisfaction of closing conditions (including certain regulatory approvals). In February BBL executive chairperson Kiran Mazumdar-Shaw had said it is looking to launch an initial public offering in the next 18-24 months.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :BioconBengaluruIrelandPharmaceutical companies

Next Story